{"id":3371,"date":"2026-07-01T07:00:00","date_gmt":"2026-07-01T07:00:00","guid":{"rendered":"https:\/\/cielcharlotte.com\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/"},"modified":"2026-07-01T07:00:00","modified_gmt":"2026-07-01T07:00:00","slug":"skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care","status":"publish","type":"post","link":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/","title":{"rendered":"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care"},"content":{"rendered":"

First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to\u2026<\/p>\n

Read the full release \u2192<\/a><\/p>\n

News provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP’s ability to\u2026<\/p>\n","protected":false},"author":14,"featured_media":3372,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-3371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\nSkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-01T07:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care\",\"datePublished\":\"2026-07-01T07:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/\"},\"wordCount\":67,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/\",\"name\":\"SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png\",\"datePublished\":\"2026-07-01T07:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte","og_description":"First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-07-01T07:00:00+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png","type":"image\/png"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care","datePublished":"2026-07-01T07:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/"},"wordCount":67,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/","name":"SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png","datePublished":"2026-07-01T07:00:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/07\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care-ai.png","width":1536,"height":1024,"caption":"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skylinedxs-merlin-cp-gep-granted-fda-breakthrough-device-designation-building-on-exclusive-nccn-recognition-in-melanoma-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/3371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=3371"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/3371\/revisions"}],"predecessor-version":[{"id":9110,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/3371\/revisions\/9110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/3372"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=3371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=3371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=3371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}